Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 301–400 of 810
Higginbotham, L. A., Carter, E. K., Dammer, E. B., Haque, R. U., Johnson, E. C. B., Duong, D. M., Yin, L., Jager, P. L. D., Bennett, D. A., Felsky, D., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106286 · Cited by 43
Cheng, S., Cao, D., Hottman, D. A., Yuan, L., Bergö, M. O., & Li, L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.503904 · Cited by 44
“ApoE and LRP1 are major proteins involved in the clearance of A in the brain (35).”
BackgroundPolsinelli, A. J., Logan, P. E., Lane, K. A., Manchella, M. K., Nemes, S., Sanjay, A. B., Gao, S., & Apostolova, L. G. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12831 · Cited by 43
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 43
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 45
Asaro, A., Carlo‐Spiewok, A., Malik, A. R., Rothe, M., Schipke, C. G., Peters, O., Heeren, J., & Willnow, T. E. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12121 · Cited by 38
“It is secreted by astrocytes and microglia and delivers essential lipids to neurons that take up apoE-bound cargo via apoE receptors (reviewed in [1]).”
BackgroundThe Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease
de Wit, N. M., Mol, K., Rodríguez‐Lorenzo, S., de Vries, H. E., & Kooij, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620348 · Cited by 42
“Next to peripheral tissues involved in cholesterol metabolism, ApoE is highly expressed in the brain where it plays an important role in lipid trafficking (15).”
BackgroundShi, L., Du, X., Zhou, H., Tao, C., Liu, Y., Meng, F., Wu, G., Xiong, Y., Xia, C., Wang, Y., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000601 · Cited by 38
“ApoE, which is mainly secreted by glial cells, plays a key role in the central nervous system (Holtzman et al., 2012).”
BackgroundO-GlcNAcylation and neuronal energy status: Implications for Alzheimer’s disease
Pinho, T. S., Verde, D. M., Correia, S. C., Cardoso, S. M., & Moreira, P. I. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.003 · Cited by 38
Sortilin, a novel APOE receptor implicated in Alzheimer disease
Carlo, A.-S. (2013) · Prion · doi:10.4161/pri.26746 · Cited by 43
“380 Prion Volume 7 issue 5 analysis of mouse models in which Ldlr or Lrp1 have been inactivated showed increased APOE levels in the brain.(6) It is well described that APOE-mediated clearance of Aβ peptides can occur at different locations in the brain.”
BackgroundInfluentialChan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016) · Scientific Reports · doi:10.1038/srep26119 · Cited by 39
Borràs, C., Mercer, A., Sirisi, S., Alcolea, D., Escolà-Gil, J. C., Blanco-Vaca, F., & Tondo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169356 · Cited by 39
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Ganglioside-Mediated Assembly of Amyloid β-Protein: Roles in Alzheimer's Disease
Matsuzaki, K., Kato, K., & Yanagisawa, K. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.10.005 · Cited by 39
Neurotrophins as Key Regulators of Cell Metabolism: Implications for Cholesterol Homeostasis
Colardo, M., Martella, N., Pensabene, D., Siteni, S., Bartolomeo, S. D., Pallottini, V., & Segatto, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115692 · Cited by 42
The Role of Sleep in Cognitive Function: The Value of a Good Night’s Rest
Gilley, R. R. (2022) · Clinical EEG and Neuroscience · doi:10.1177/15500594221090067 · Cited by 49
Carter, C. J. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12077 · Cited by 38
“APOE is concerned with the transport of cholesterol, a major myelin constituent, also indispensable for cerebral function and plasticity (Bjorkhem & Meaney, 2004; Holtzman et al., 2012).”
BackgroundConcerning the structure of apoE
Frieden, C., & Garai, K. (2013) · Protein Science · doi:10.1002/pro.2379 · Cited by 38
“ance with clearance by apoE4 being slower than that by apoE3 or apoE2.(32,34) For example, LaDu and coworkers find that Ab accumulation is apoE isoform dependent in a transgenic mouse model.”
BackgroundInflammation as a Possible Link Between Dyslipidemia and Alzheimer’s Disease
Oliveira, B. C. D. L., Bellozi, P. M. Q., Reis, H. J., & de Oliveira, A. C. P. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.012 · Cited by 43
Altered SPMs and age‐associated decrease in brain DHA in APOE4 female mice
Martinsen, A., Tejera, N., Vauzour, D., Harden, G., Dick, J., Shinde, S., Barden, A. E., Mori, T. A., & Minihane, A. M. (2019) · The FASEB Journal · doi:10.1096/fj.201900423r · Cited by 41
“Within theCNS, theAPOEprotein performs numerous roles including synaptic plasticity maintenance, cell signaling, neuroinflammation modulation, and lipid transport and metabolism (7).”
BackgroundSalami, A., Adolfsson, R., Andersson, M., Blennow, K., Lundquist, A., Adolfsson, A. N., Schöll, M., Zetterberg, H., & Nyberg, L. H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210673 · Cited by 43
“A likely mechanism by which the APOE 4 allele increases risk for AD is through influencing amyloid- (A ) deposition [2].”
BackgroundReducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer’s Disease
Yang, S., Du, Y., Zhao, X., Wu, C., & Yu, P. (2022) · Cells · doi:10.3390/cells11111735 · Cited by 43
Passarella, D., Ciampi, S., Liberto, V. D., Zuccarini, M., Ronci, M., Medoro, A., Foderà, E., Frinchi, M., Mignogna, D., Russo, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168921 · Cited by 40
“In fact, LRP8 is a γ-secretase substrate, like APP and other LDL members such as LRP1 [169], LRP1b [170], LRP2 [171], LRP6 [172], LR11 [173] and VLDLR [174] as well as many other substrates including Notch [175–178].”
BackgroundAstrocytic microRNAs and transcription factors in Alzheimer’s disease and therapeutic interventions
Nassar, A., Kodi, T., Satarker, S., Chowdari Gurram, P., Upadhya, D., SM, F., Mudgal, J., & Nampoothiri, M. (2022) · Cells · doi:10.3390/cells11244111 · Cited by 38
“Astrocytes are the major producers of ApoE, which is principally linked to cholesterolrich high-density lipoprotein (HDL)-like complexes and also the prime source of cholesterol transport in neurons [24].”
BackgroundAPOEgene and neuropsychiatric disorders and endophenotypes: A comprehensive review
Forero, D. A., López‐León, S., González‐Giraldo, Y., Dries, D. R., Pereira‐Morales, A. J., Jiménez, K. M., & Franco‐Restrepo, J. E. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32516 · Cited by 41
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Kang, R., Li, P., Wang, T., Li, X., Wei, Z., Zhang, Z., Zhong, L., Cao, L., Heckman, M. G., Zhang, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep19930 · Cited by 39
Self-citationSirtuin 3 (SIRT3) Pathways in Age-Related Cardiovascular and Neurodegenerative Diseases
Silaghi, C. N., Farcas, M. F., & Craciun, A. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111574 · Cited by 39
The Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121060 · Cited by 34
“Apolipoprotein (APO) E, a reactive apolipoprotein that was initially recognized for its major functions in the transport and metabolism of lipids and cholesterol in our body [54–57], is now known to be associated with several cardiovascular, immunological, and neurodegenerative diseases such as atherosclerosis,”
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Zhang, W., Hu, C., Yang, Z., Zhou, Q., Peng, D., Yuan, X., Lv, Z., Pang, S., Jiang, W., Yang, C., et al. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.130117 · Cited by 36
“ApoE isoform-mediated differential effects in Aβ metabolism result in different brain Aβ aggregation (ε4 > ε3 > ε2) (Holtzman et al., 2012), an upstream event known to trigger AD onset (Sperling et al.”
BackgroundDubey, H., Gulati, K., & Ray, A. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0049 · Cited by 36
Iacono, D., & Feltis, G. C. (2019) · Aging · doi:10.18632/aging.101757 · Cited by 37
“ApoE transfers cholesterol to neurons and represents an essential molecule for neuronal growth, synaptic plasticity, and membrane reparative processes [37].”
BackgroundNam, K. N., Mounier, A., Fitz, N. F., Wolfe, C., Schug, J., Lefterov, I., & Koldamova, R. (2016) · Scientific Reports · doi:10.1038/srep24048 · Cited by 36
Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation
Shippy, D. C., & Ulland, T. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41897-6 · Cited by 35
“Additionally, several mouse microglial lipid metabolism DEGs localized in the caveolae, including low density lipoprotein receptor ( Ldlr ) which is a primary metabolic receptor responsible for ApoE lipoprotein clearance 55,56 .”
BackgroundZhang, M., Gong, W., Zhang, D., Ji, M. H., Chen, B., Chen, B., Li, X., Zhou, Y., Dong, C., Wen, G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04858-x · Cited by 37
MAM and C99, key players in the pathogenesis of Alzheimer’s disease
Pera, M., Montesinos, J., Larrea, D., Agrawal, R. R., VELASCO, K. R., Stavrovskaya, I. G., Yun, T. D., & Área-Gómez, E. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.016 · Cited by 37
The Interplay Between Apolipoprotein E4 and the Autophagic–Endocytic–Lysosomal Axis
Schmukler, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0892-4 · Cited by 35
“assumed to undergo clathrin-mediated endocytosis following ligand binding, it is likely that the effect of apoE4 is mostly relevant to this type of endocytic pathway [21, 79].”
BackgroundLagger, C., Ursu, E., Equey, A., Avelar, R. A., Pisco, A. O., Tăcutu, R., & de Magalhães, J. P. (2023) · Nature Aging · doi:10.1038/s43587-023-00514-x · Cited by 36
“App is the precursor of amyloid beta (Aβ) peptides 82 ; Apoe is a known regulator of Aβ clearance 83 ; and interactions between App and Apoe receptors influence Aβ metabolism and toxicity 84,85 .”
BackgroundShastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 36
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
Lautner, R., Insel, P. S., Skillbäck, T. B., Olsson, B., Landén, M., Frisoni, G. B., Herukka, S., Hampel, H. J., Wallin, A., Minthon, L., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0313-3 · Cited by 36
“Heterozygous APOE ε4 carriers have an approximately 3-fold increase of risk compared with individuals lacking the ε4 allele, whereas the increase of risk is up to 12-fold in homozygous APOE ε4 carriers [3].”
The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer’s Disease
Qin, Q., Wang, M., Yin, Y., & Tang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845897 · Cited by 40
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 39
“Moreover, the gene acts in a dose-dependent manner, with one ε4 allele increasing the risk of AD by ~3- to 4-fold and two ε4 alleles increasing the risk by ~12-fold (2, 4).”
BackgroundSelf-citationEfficient creation of an APOE knockout rabbit
Ji, D., Zhao, G., Songstad, A. E., Cui, X., & Weinstein, E. J. (2014) · Transgenic Research · doi:10.1007/s11248-014-9834-8 · Cited by 37
“Apo-E is one of the best characterized apolipoproteins and plays critical roles in lipid transport, cholesterol homeostasis and health of the central nervous system (Hauser et al. 2011; Holtzman et al. 2012; Kanekiyo et al. 2014).”
Krishnan, M., Hwang, J. S., Kim, M. K., Kim, Y. J., Seo, J. H., Jung, J., & Ha, E. (2020) · Nutrients · doi:10.3390/nu12020471 · Cited by 35
“People with apoE4 allele are susceptible to late onset AD [2,3].”
BackgroundAPOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
“It has been well-established that polymorphism in the APOE gene is one the strongest genetic predictors of sporadic Alzheimer’s disease (AD) risk [69].”
BackgroundSMPD3 deficiency perturbs neuronal proteostasis and causes progressive cognitive impairment
Stoffel, W., Jenke, B., Schmidt‐Soltau, I., Binczek, E., Brodesser, S., & Hammels, I. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0560-7 · Cited by 36
Marca-Ysabel, M. V., Rajabli, F., Cornejo‐Olivas, M., Whitehead, P. G., Hofmann, N. K., Illanes‐Manrique, M., Véliz-Otani, D., Milla‐Neyra, K., Castro‐Suárez, S., Meza-Vega, M., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.003 · Cited by 37
Kim, S. H., Adhikari, B. B., Cruz, S., Schramm, M. P., Vinson, J. A., & Narayanaswami, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135130 · Cited by 33
“Whereas LDL is not a ligand for LRP, apoE is a well-established ligand, and plays an important role in binding and uptake of apoE containing lipoproteins[47, 48] especially in the central nervous system.”
BackgroundReduced neuronal signaling in the ageing apolipoprotein-E4 targeted replacement female mice
Yong, S.-M., Lim, M.-L., Low, C.-M., & Wong, B.-S. (2014) · Scientific Reports · doi:10.1038/srep06580 · Cited by 31
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Membrane lipid domains in the nervous system
Sonnino, S., Aureli, M., Mauri, L., Ciampa, M. G., & Prinetti, A. (2015) · Frontiers in bioscience · doi:10.2741/4309 · Cited by 38
New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics
Lutz, M. W., Crenshaw, D. G., Welsh-Bohmer, K. A., Burns, D. K., & Roses, A. D. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0643-8 · Cited by 34
Assessing for interaction betweenAPOEε4, sex, and lifestyle on cognitive abilities
Lyall, D. M., Celis-Morales, C. A., Lyall, L. M., Graham, C. D., Graham, N., Mackay, D., Strawbridge, R. J., Ward, J., Gill, J. M. R., Sattar, N. A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007551 · Cited by 35
“The potential biological rationale for this is that the APOE locus moderates lipid metabolism, which influences brain-relevant factors like white matter myelination and neuronal repair, meaning e4 carriers may be more frail and vulnerable to the negative effects of suboptimal lifestyle risk factors.(9,10) There have b…”
BackgroundADAM10 Prodomain Mutations Cause Late-Onset Alzheimer’s Disease: Not Just the Latest FAD
Vassar, R. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.031 · Cited by 32
Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model
Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt525 · Cited by 32
“Whereas the low-density lipoprotein receptor mainly mediates uptake of APOE into microglia and astrocytes (37), low-density lipoprotein receptor-related protein 1 constitutes an uptake pathway for this apolipoprotein in neurons (17).”
BackgroundThe role of the ATP-Binding Cassette A1 (ABCA1) in neurological disorders: a mechanistic review
Paseban, T., Alavi, M. S., Etemad, L., & Roohbakhsh, A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2235718 · Cited by 34
“On the other hand, ABCA1 controls apoE level and highly lipidated apoE binds more efficiently to Aβ [82].”
BackgroundRelationship between long non-coding RNAs and Alzheimer’s disease: a systematic review
Chen, L., Guo, X., Li, Z., & He, Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.11.012 · Cited by 33
Benson, G. S., Bauer, C., Hausner, L., Couturier, S. P., Lewczuk, P., Peters, O., Hüll, M., Jahn, H., Jessen, F., Pantel, J., et al. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02461-0 · Cited by 35
“Heterozygous ApoE4 carriers have an approximately fourfold increase of risk compared with the most prevalent homozygous carriers of the ε3 allele, whereas in homozygous ApoE4 carriers, the increase of risk is approximately 12-fold (Holtzman et al. 2012).”
BackgroundZhao, H., Huang, M., & Jiang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216149 · Cited by 34
“AD is caused by various factors, such as aging, smoking, obesity, diabetes, etc. [106,107].”
BackgroundAPOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease
Singh, N. K., Banerjee, B. D., Bala, K., Mitrabasu, Dung Dung, A. A., & Chhillar, N. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1651-6 · Cited by 31
Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
Petros, A. M., Korepanova, A., Jakob, C. G., Qiu, W., Panchal, S. C., Wang, J., Dietrich, J. D., Brewer, J. T., Pohlki, F., Kling, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00178 · Cited by 32
Genetics of Alzheimer’s disease
König, T., & Stögmann, E. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00819-9 · Cited by 37
Trease, A. J., George, J. W., Roland, N. J., Lichter, E. Z., Emanuel, K. M., Totusek, S., Fox, H. S., & Stauch, K. L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.852368 · Cited by 32
“Notably, precise mechanisms by which the ε4 allele increases AD risk are currently controversial, however, the ε4 allele is associated with enhanced oxidative stress, more severe amyloid pathology (Holtzman et al., 2012), disruption of neuronal signaling, and—most relevant to our study—altered phosphorylation of tau a…”
BackgroundMolecular recognition of the interaction between ApoE and the TREM2 protein
Mai, Z., Wei, W., Yu, H., Chen, Y., Wang, Y., & Ding, Y. (2022) · Translational Neuroscience · doi:10.1515/tnsci-2022-0218 · Cited by 33
“These differences significantly affect the structure and stability of the ApoE protein and its ability to bind to lipids and receptors, which is considered the structural basis by which ApoE4 accelerates the pathological process of AD [4,5].”
BackgroundYao, Q., Jiang, K., Lin, F., Zhu, T., Khan, N. H., & Jiang, E. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s400527 · Cited by 31
Role of LDL Cholesterol and Endolysosomes in Amyloidogenesis and Alzheimer’s Disease
Chen, X. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000236 · Cited by 30
Mendiola-Precoma, J., Padilla, K., Rodríguez-Cruz, A., Berumen, L. C., Miledi, R., & García‐Alcocer, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160569 · Cited by 33
Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications
Portioli, C., Bovi, M., Benati, D., Donini, M., Perduca, M., Romeo, A., Dusi, S., Monaco, H. L., & Bentivoglio, M. (2016) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35961 · Cited by 35
Sleep Fragmentation and Cognitive Trajectories After Critical Illness
Wilcox, M. E., McAndrews, M. P., Van, J., Jackson, J. C., Pinto, R. L., Black, S. E., Lim, A. S. P., Friedrich, J. O., & Rubenfeld, G. D. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.036 · Cited by 33
Opposing Roles of apolipoprotein E in aging and neurodegeneration
Hudry, E., Klickstein, J., Cannavo, C., Jackson, R., Muzikansky, A., Gandhi, S., Urick, D., Sargent, T., Wrobleski, L., Roe, A. D., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900325 · Cited by 30
“…between A β and speci fi c cellular receptors (such as APP itself, as recently reported [Wang et al, 2017], TREM2 [Yeh et al, 2016], or any other APOE receptors [Holtzman et al, 2012; Lane-Donovan & Herz, 2017]) to initiate various deleterious molecular cascades in neurons or even in glial cells.”
BackgroundCholesterol Metabolism in Neurodegenerative Diseases
He, K., Zhao, Z., Zhang, J., Li, D., Wang, S., & Liu, Q. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0674 · Cited by 32
“2) (Holtzman et al., 2012).”
APOE effects on cognition from childhood to adolescence
Reynolds, C. A., Smolen, A., Corley, R. P., Muñoz, E., Friedman, N. P., Rhee, S. H., Stallings, M. C., DeFries, J. C., & Wadsworth, S. J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.011 · Cited by 34
“The APOE gene encodes the brain’s primary cholesterol transporter, apolipoprotein E, which may play additional roles in synaptic plasticity and cell signaling (Holtzman et al., 2012).”
BackgroundJeong, A., Cheng, S., Zhong, R., Bennett, D. A., Bergö, M. O., & Li, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01231-5 · Cited by 32
Zhang, Y., Gao, H., Zheng, W., & Xu, H. J. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105824 · Cited by 32
The Role of ApoE in HCV Infection and Comorbidity
Gong, Y., & Cun, W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082037 · Cited by 32
Liang, Y., Raven, F., Ward, J. F., Zhen, S. Y., Zhang, S., Sun, H., Miller, S., Choi, S. H., Tanzi, R. E., & Zhang, C. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200128 · Cited by 32
“In late-onset AD, ApoE protein is highly expressed in the brain, primarily in astrocytes [15].”
A Dichotomous Role for FABP7 in Sleep and Alzheimer’s Disease Pathogenesis: A Hypothesis
Needham, H., Torpey, G., Flores, C. C., Davis, C. J., Vanderheyden, W. M., & Gerstner, J. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.798994 · Cited by 29
The novel function of bexarotene for neurological diseases
Liu, Y., Wang, P., Jin, G., Shi, P., Zhao, Y., Guo, J., Yin, Y., Shao, Q.-H., Li, P., & Yang, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102021 · Cited by 32
Chan, E. S., Chen, C., Cole, G. M., & Wong, B.-S. (2015) · Scientific Reports · doi:10.1038/srep13842 · Cited by 29
Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins
Strickland, M. R., Rau, M. J., Summers, B., Basore, K., Wulf, J., Jiang, H., Chen, Y., Ulrich, J. D., Randolph, G. J., Zhang, R., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.018 · Cited by 28
Self-citationJia, L., Chen, Y., Li, H., Zhao, K., Ge, S., Wang, C., Zhao, J., Li, F., Zhang, L., & Yao, A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02203-9 · Cited by 29
Relationship Between Genetic Risk Factors and Markers for Alzheimer’s Disease Pathology
Elias-Sonnenschein, L. S., Bertram, L., & Visser, P. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.56 · Cited by 29
The MUC6/AP2A2 Locus and Its Relevance to Alzheimer’s Disease: A Review
Nelson, P. T., Fardo, D. W., & Katsumata, Y. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa024 · Cited by 31
Hollinger, K. R., Zhu, X., Khoury, E. S., Thomas, A. G., Liaw, K., Tallon, C., Wu, Y., Prchalová, E., Kamiya, A., Rojas, C. J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190588 · Cited by 30
“Similar to human carriers, APOE4 mice experience learning and memory difficul-ties, accelerated development of A (cid:2) plaques, and impaired A (cid:2) clearance [23, 24].”
Asaro, A., Sinha, R., Bakun, M., Kalnytska, O., Carlo-Spiewok, A.-S., Rubel, T., Rozeboom, A., Dadlez, M., Kaminska, B., Aronica, E., et al. (2021) · Journal of Cell Science · doi:10.1242/jcs.258894 · Cited by 31
The immune-suppressive landscape in lepromatous leprosy revealed by single-cell RNA sequencing
Mi, Z., Wang, Z., Xue, X., Liu, T., Wang, C., Sun, L., Yu, G., Zhang, Y., Shi, P., Sun, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00353-3 · Cited by 31
Mattar, J. M., Majchrzak, M., Iannucci, J., Bartman, S., Robinson, J. K., & Grammas, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073921 · Cited by 32
“Numerous studies have reported elevated biomarkers of oxidative stress and neuroinflammation in animals fed a WD [29,30,36,37].”
BackgroundResultDefects of Nutrient Signaling and Autophagy in Neurodegeneration
Ondaro, J., Hernández-Eguiazu, H., Garciandia-Arcelus, M., Loera‐Valencia, R., Rodríguez-Gómez, L., Jiménez-Zúñiga, A., Goikolea, J., Rodriguez‐Rodriguez, P., Ruiz‐Martínez, J., Moreno, F., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.836196 · Cited by 29
Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease
Jovanovic, K., Gonsalves, D., Dias, B. D. C., Moodley, K., Reusch, U., Knackmuss, S. H. J., Penny, C. B., Weinberg, M. S., Little, M., & Weiss, S. F. T. (2013) · Scientific Reports · doi:10.1038/srep02699 · Cited by 31
Saul, A., & Wirths, O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9674-4 · Cited by 28
“There is now substantial evidence that ApoE, and in particular ApoE4, affect AD risk by differential mechanisms of ApoE isoforms on amyloid-β (Aβ) aggregation and clearance [3, 4].”
BackgroundHöfling, C., Morawski, M., Zeitschel, U., Zanier, E. R., Moschke, K., Serdaroglu, A., Canneva, F., Hörsten, S., De Simoni, M., Forloni, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12508 · Cited by 24
“Many APP-transgenic mouse models have been crossed to other transgenic/knockout mouse models to study their effect on amyloid deposition/clearance (Holtzman et al., 2012).”
BackgroundA short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
Seneviratne, U. I., Huang, Z., Ende, C. W. A., Butler, T. W., Cleary, L., Dresselhaus, E. C., Evrard, E., Fisher, E. L., Green, M. E., Helal, C. J., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.09.002 · Cited by 30
Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment
Stowe, A. M., Ireland, S. J., Ortega, S. B., Chen, D., Huebinger, R. M., Tarumi, T., Harris, T. S., Cullum, C. M., Rosenberg, R. N., Monson, N. L., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0910-x · Cited by 42
APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer’s disease
Wang, S., Zhang, J., & Pan, T. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.029 · Cited by 30
Lipid mediated brain disorders: A perspective
Singh, A., Kukal, S., Kanojia, N., Singh, M., Saso, L., Kukreti, S., & Kukreti, R. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106737 · Cited by 28
Kanimozhi, V., Kandasamy, P., Akbarsha, M. A., & Kadalmani, B. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26564 · Cited by 27
“The binding of ApoE to certain LDL receptor family members not only leads to endocytosis and subsequent importation of lipid-protein complex into the cells but also initiates signal transduction.(44) The cellular functions of ApoE are less well understood, but it may play role as an autocrine or paracrine growth facto…”
BackgroundWang, H., Xiao, L., Wang, G., & Wang, G. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.112749 · Cited by 29
Na, H., Yang, J. B., Zhang, Z., Gan, Q., Tian, H., Rajab, I. M., Potempa, L. A., Tao, Q., & Qiu, W. Q. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.02.013 · Cited by 27
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.